Screening for the Presence of Aberrantly Expressed ACTR2 in Osteosarcoma and Analyzing Its Mechanism of Action Through an Online Database

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2024 Sep 13

PMID 39267681

Authors

Min Yi

Kai Zheng

Qian Ning

Yu Nie

Fuguo Huang

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma (OS) represents the most prevalent malignant bone tumor clinically, significantly impacting the health and safety of patients. The exploration of molecular pathogenic mechanisms is deemed a breakthrough for OS diagnosis and treatment. Within the GSE16088 dataset, a total of 1,948 differentially expressed genes (DEGs) were identified, comprising 1,697 down-regulated and 251 up-regulated genes. Notably, only two DEGs were associated with the response to trichostatin A: ARP2 actin-related protein 2 homolog (ACTR2) and MEF2C; ACTR2 garnered particular interest. Subsequently, 57 OS patients (research group) and 50 healthy controls from the same period (control group) were selected for analysis. The expression of ACTR2 in peripheral blood in both groups, as well as its levels in cancerous tissues and adjacent counterparts of OS patients, were evaluated, ascertaining the correlation between ACTR2 and OS. OS cases exhibited lower levels of ACTR2 compared to controls (P<0.05), with ACTR2 expression demonstrating a robust diagnostic capability for OS. Similarly, ACTR2 expression was diminished in cancer tissues (P<0.05). A three-year prognostic follow-up was conducted to assess the prognostic value of ACTR2 in OS patients. The follow-up findings revealed a significantly lower survival rate among patients with low ACTR2 expression in contrast to those with high expression (P<0.05). In vitro studies involved the construction of abnormal expression vectors for ACTR2 and miR-374a-5p, which were transfected into human OS cells (U2OS, SAOS). The outcomes indicated that elevating ACTR2 or suppressing miR-374a-5p attenuated the proliferative, invasive, and migratory capacities as well as the epithelial-mesenchymal transition (EMT) of OS cells while enhancing their apoptosis. Conversely, upregulation of miR-374a-5p yielded opposing effects (P<0.05). The dual-luciferase reporter (DLR) assay demonstrated that the fluorescence activity of ACTR2-WT was significantly inhibited by the miR-374a-5p mimic sequence (P<0.05), confirming the presence of a targeted regulatory relationship between ACTR2 and miR-374a-5p. These findings offer novel insights for future research directions in the diagnosis and treatment of OS.

References

Chen C, Liu L . Silencing of lncRNA KLF3-AS1 represses cell growth in osteosarcoma via miR-338-3p/MEF2C axis. J Clin Lab Anal. 2022; 36(11):e24698. PMC: 9701870. DOI: 10.1002/jcla.24698. View

Ghafouri-Fard S, Shirvani-Farsani Z, Hussen B, Taheri M . The critical roles of lncRNAs in the development of osteosarcoma. Biomed Pharmacother. 2021; 135:111217. DOI: 10.1016/j.biopha.2021.111217. View

Tan J, Liang H, Yang B, Zhu S, Wu G, Li L . Identification and Analysis of Three Hub Prognostic Genes Related to Osteosarcoma Metastasis. J Oncol. 2021; 2021:6646459. PMC: 7867449. DOI: 10.1155/2021/6646459. View

He X, Fang J, Gong M, Zhang J, Xie R, Zhao D . Identification of immune-associated signatures and potential therapeutic targets for pulmonary arterial hypertension. J Cell Mol Med. 2023; 27(23):3864-3877. PMC: 10718157. DOI: 10.1111/jcmm.17962. View

Dongre A, Weinberg R . New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2018; 20(2):69-84. DOI: 10.1038/s41580-018-0080-4. View

Cheng D, Yang Q, Zhang Z, Yang C, Liu Y . Antitumor activity of histone deacetylase inhibitor trichostatin A in osteosarcoma cells. Asian Pac J Cancer Prev. 2012; 13(4):1395-9. DOI: 10.7314/apjcp.2012.13.4.1395. View

Ali T, Grote P . Beyond the RNA-dependent function of LncRNA genes. Elife. 2020; 9. PMC: 7584451. DOI: 10.7554/eLife.60583. View

Belayneh R, Fourman M, Bhogal S, Weiss K . Update on Osteosarcoma. Curr Oncol Rep. 2021; 23(6):71. DOI: 10.1007/s11912-021-01053-7. View

Bai Y, Chen Y, Chen X, Jiang J, Wang X, Wang L . Trichostatin A activates FOXO1 and induces autophagy in osteosarcoma. Arch Med Sci. 2019; 15(1):204-213. PMC: 6348367. DOI: 10.5114/aoms.2018.73860. View

10.

Guo Q, Wang H, Xu Y, Wang M, Tian Z . miR-374a-5p inhibits non-small cell lung cancer cell proliferation and migration via targeting NCK1. Exp Ther Med. 2021; 22(3):943. PMC: 8281440. DOI: 10.3892/etm.2021.10375. View

11.

Zhao Z, Sun W, Guo Z, Zhang J, Yu H, Liu B . Mechanisms of lncRNA/microRNA interactions in angiogenesis. Life Sci. 2019; 254:116900. DOI: 10.1016/j.lfs.2019.116900. View

12.

Gill J, Gorlick R . Advancing therapy for osteosarcoma. Nat Rev Clin Oncol. 2021; 18(10):609-624. DOI: 10.1038/s41571-021-00519-8. View

13.

Eaton B, Claude L, Indelicato D, Vatner R, Yeh B, Schwarz R . Ewing sarcoma. Pediatr Blood Cancer. 2021; 68 Suppl 2:e28355. DOI: 10.1002/pbc.28355. View

14.

Bridges M, Daulagala A, Kourtidis A . LNCcation: lncRNA localization and function. J Cell Biol. 2021; 220(2). PMC: 7816648. DOI: 10.1083/jcb.202009045. View

15.

Ji R, Zhang X, Gu H, Ma J, Wen X, Zhou J . miR-374a-5p: A New Target for Diagnosis and Drug Resistance Therapy in Gastric Cancer. Mol Ther Nucleic Acids. 2019; 18:320-331. PMC: 6796712. DOI: 10.1016/j.omtn.2019.07.025. View

16.

Shoaib Z, Fan T, Irudayaraj J . Osteosarcoma mechanobiology and therapeutic targets. Br J Pharmacol. 2021; 179(2):201-217. PMC: 9305477. DOI: 10.1111/bph.15713. View

17.

Wang J, Yang Y, Ma Y, Wang F, Xue A, Zhu J . Potential regulatory role of lncRNA-miRNA-mRNA axis in osteosarcoma. Biomed Pharmacother. 2019; 121:109627. DOI: 10.1016/j.biopha.2019.109627. View

18.

Lian F, Cui Y, Zhou C, Gao K, Wu L . Identification of a plasma four-microRNA panel as potential noninvasive biomarker for osteosarcoma. PLoS One. 2015; 10(3):e0121499. PMC: 4361617. DOI: 10.1371/journal.pone.0121499. View

19.

Deng Z, Liu X, Jin J, Xu H, Gao Q, Wang Y . Histone Deacetylase Inhibitor Trichostatin a Promotes the Apoptosis of Osteosarcoma Cells through p53 Signaling Pathway Activation. Int J Biol Sci. 2016; 12(11):1298-1308. PMC: 5118776. DOI: 10.7150/ijbs.16569. View

20.

Chen D, Jiang L . Upregulation of Actin-Related Protein 2 (ACTR2) Exacerbated the Malignancy of Diffuse Large B-Cell Lymphoma through Activating Wnt Signaling. Comput Math Methods Med. 2022; 2022:9351921. PMC: 9771665. DOI: 10.1155/2022/9351921. View